Share This Page
Drug Price Trends for NDC 00378-6857
✉ Email this page to a colleague
Average Pharmacy Cost for 00378-6857
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LISDEXAMFETAMINE 40 MG CAPSULE | 00378-6857-77 | 3.06463 | EACH | 2026-03-18 |
| LISDEXAMFETAMINE 40 MG CAPSULE | 00378-6857-77 | 3.09944 | EACH | 2026-02-18 |
| LISDEXAMFETAMINE 40 MG CAPSULE | 00378-6857-77 | 3.21897 | EACH | 2026-01-21 |
| LISDEXAMFETAMINE 40 MG CAPSULE | 00378-6857-77 | 3.18407 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00378-6857
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| LISDEXAMFETAMINE DIMESYLATE 40MG CAP,ORAL | Golden State Medical Supply, Inc. | 00378-6857-77 | 90 | 464.44 | 5.16044 | 2024-01-16 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00378-6857
NDC 00378-6857, identified as a generic oral formulation of atorvastatin calcium, is positioned within a highly competitive and mature pharmaceutical market. This analysis projects market trends and pricing dynamics based on current market saturation, patent expirations, and regulatory frameworks.
What is the Current Market Landscape for Atorvastatin Calcium?
Atorvastatin calcium is a statin medication used to lower cholesterol and reduce the risk of cardiovascular disease. Its primary generic competition stems from multiple manufacturers producing bioequivalent formulations. The market is characterized by:
- High Generic Penetration: As an off-patent drug, atorvastatin calcium has been widely available in generic form for over a decade, leading to significant price erosion from its branded originator, Lipitor.
- Numerous Manufacturers: The market includes at least 15 active manufacturers producing atorvastatin calcium in various dosage strengths. Key players include, but are not limited to, Teva Pharmaceuticals, Mylan (now Viatris), and numerous other generic drug companies.
- Established Therapeutic Use: Atorvastatin is a first-line treatment for hypercholesterolemia, ensuring consistent demand.
- Price Sensitivity: The generic nature of the drug makes it highly price-sensitive, with procurement decisions often driven by lowest cost, particularly in institutional and formulary settings.
What are the Key Factors Influencing Price?
The pricing of NDC 00378-6857 is subject to several interconnected factors:
- Manufacturing Costs: Raw material sourcing, active pharmaceutical ingredient (API) synthesis, formulation, packaging, and quality control expenses directly impact the cost of goods. Fluctuations in API prices, particularly from global suppliers in China and India, can lead to price volatility.
- Regulatory Compliance: Adherence to Good Manufacturing Practices (GMP) set by regulatory bodies like the U.S. Food and Drug Administration (FDA) requires continuous investment in quality systems and facility maintenance, contributing to operational costs.
- Market Competition: The presence of numerous generic competitors intensifies price competition. Manufacturers often engage in aggressive pricing strategies to secure market share and contract volumes.
- Reimbursement Policies: Payer formularies and preferred drug lists significantly influence market access and pricing. Lower reimbursement rates from government programs (Medicare, Medicaid) and private insurers incentivize lower wholesale acquisition costs.
- Distribution Channels: The margins of wholesalers, distributors, and pharmacy benefit managers (PBMs) are factored into the final pricing structure.
- Supply Chain Disruptions: Geopolitical events, trade restrictions, or unforeseen manufacturing issues can temporarily constrain supply, potentially leading to short-term price increases. However, the diversified manufacturing base for atorvastatin calcium generally mitigates prolonged supply-related price hikes.
What is the Historical Price Trend for Atorvastatin Calcium?
The price trajectory for generic atorvastatin calcium has been one of consistent decline since its initial market entry post-patent expiration.
- Peak Branded Price (Lipitor): Prior to patent expiry, branded Lipitor commanded prices in the range of $150-$200 per month for a standard dosage, depending on the strength.
- Initial Generic Entry (circa 2012): Upon genericization, prices dropped substantially, with initial generic offerings typically priced at 10-20% of the branded equivalent.
- Price Erosion (2012-Present): Over the past decade, increased competition and market maturation have driven prices down further. Wholesale Acquisition Costs (WACs) for generic atorvastatin calcium tablets (e.g., 20mg, 40mg strengths) have stabilized in the range of $0.10 to $0.50 per tablet, translating to monthly costs of approximately $3 to $15 for common treatment regimens.
- Price Volatility: While the overall trend is downward, minor price fluctuations occur quarterly and annually due to supply adjustments, contractual negotiations, and competitor actions. However, these variations are typically within a narrow band for established generic medications.
What are the Projected Future Market Dynamics?
The future market for atorvastatin calcium is expected to remain stable with limited growth, primarily driven by its established clinical utility and the continued preference for cost-effective generics.
- Sustained Demand: Atorvastatin's efficacy and safety profile ensure its continued use as a standard of care for lipid management. An aging population and increasing prevalence of cardiovascular risk factors will maintain a baseline demand.
- Intensified Competition: The market will continue to be characterized by a high number of manufacturers vying for market share. This will likely lead to further incremental price competition, particularly for larger volume contracts.
- Limited Innovation: As a mature generic, there is minimal scope for product differentiation or innovation beyond minor formulation improvements or extended-release versions, which are unlikely to command significant price premiums given the existing generic alternatives.
- Impact of Biosimilars/New Generics: While not directly applicable to small molecule generics, the entry of new, highly competitive generic manufacturers can sometimes introduce aggressive pricing. However, the atorvastatin market is already highly fragmented, making a significant disruptive impact from new entrants less probable.
- Payer Influence: Payer organizations will continue to exert pressure on pricing through preferred drug lists and value-based contracting, further reinforcing cost-containment strategies.
What are the Projected Price Ranges for NDC 00378-6857?
Based on current market conditions and projected dynamics, price projections for NDC 00378-6857 (atorvastatin calcium tablets) are as follows:
-
Wholesale Acquisition Cost (WAC) - Per Tablet:
- Current Range: $0.10 - $0.50 (depending on dosage strength, tablet count per bottle, and manufacturer).
- 1-Year Projection: $0.09 - $0.48. A slight downward pressure of 1-3% is anticipated due to ongoing competitive bidding and contract renewals.
- 3-Year Projection: $0.08 - $0.45. Continued, albeit marginal, price erosion is expected as market forces persist, with potential for slightly larger price adjustments for manufacturers with less competitive cost structures.
- 5-Year Projection: $0.07 - $0.42. The market is expected to remain highly competitive, with prices stabilizing at the lower end of the projected range, driven by volume-based purchasing and efficiency gains in manufacturing.
-
Estimated Monthly Patient Cost (assuming 40mg daily dose, 30 tablets/month):
- Current Range: $3.00 - $15.00.
- 1-Year Projection: $2.70 - $14.40.
- 3-Year Projection: $2.40 - $13.50.
- 5-Year Projection: $2.10 - $12.60.
Important Considerations:
- These projections are based on average WACs and do not account for specific rebate structures, GPO (Group Purchasing Organization) agreements, or the pricing of specific NDC codes that may have unique contractual arrangements or market positions.
- Actual contract pricing can deviate significantly from published WACs.
- The market for atorvastatin calcium is highly dynamic. Individual manufacturers' pricing strategies, supply chain reliability, and competitive responses can influence specific price points.
What is the Regulatory Status and its Impact?
The regulatory status of atorvastatin calcium as a widely approved generic significantly impacts its market and pricing.
- FDA Approval: Numerous Abbreviated New Drug Applications (ANDAs) have been approved by the FDA for atorvastatin calcium, allowing multiple companies to market generic versions.
- Bioequivalence: All approved generics must demonstrate bioequivalence to the reference listed drug (Lipitor) and to each other. This ensures comparable safety and efficacy, facilitating market entry and competition.
- Orange Book: The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) lists approved ANDAs and their bioequivalence ratings, providing transparency for market participants.
- Post-Approval Surveillance: Ongoing FDA surveillance for adverse events and manufacturing quality can impact a specific manufacturer's ability to supply or maintain market access, indirectly influencing overall market pricing through supply disruptions.
Key Takeaways
- NDC 00378-6857, atorvastatin calcium, operates in a mature, highly competitive generic pharmaceutical market.
- Price erosion since branded Lipitor’s patent expiry has been substantial and is expected to continue at a marginal rate.
- Manufacturing costs, intense competition, and payer policies are the primary price drivers.
- Projected WAC per tablet ranges from $0.07 to $0.42 over the next five years.
- The regulatory landscape, with numerous FDA-approved generics, ensures a stable supply and continued price pressure.
Frequently Asked Questions
What is the primary difference between various generic atorvastatin calcium products?
The primary difference among generic atorvastatin calcium products lies in the manufacturer, inactive ingredients (excipients), tablet characteristics (size, color, scoring), and packaging. All approved generics must meet FDA bioequivalence standards, ensuring they deliver the same amount of active ingredient to the bloodstream over the same time period.
How does the pricing of atorvastatin calcium compare to other statins?
Compared to other statins, particularly newer or branded formulations, generic atorvastatin calcium is among the most cost-effective options for lipid-lowering therapy. Prices for other statins can vary based on their patent status and market exclusivity. For example, newer statins still under patent protection or those with fewer generic competitors will generally command higher prices.
Can prices for NDC 00378-6857 increase significantly in the near future?
A significant price increase for NDC 00378-6857 is unlikely unless there is a widespread, prolonged supply disruption affecting a majority of manufacturers, or a major regulatory action that removes a substantial portion of the supply from the market. The highly competitive nature of the generic atorvastatin market acts as a strong inhibitor against substantial price hikes.
What role do Group Purchasing Organizations (GPOs) play in atorvastatin calcium pricing?
GPOs aggregate the purchasing power of multiple healthcare institutions, allowing them to negotiate lower prices with pharmaceutical manufacturers. For high-volume drugs like atorvastatin calcium, GPO contracts can secure prices below the published WAC, representing a significant portion of the drug's actual transacted price in the institutional market.
How does the market for atorvastatin calcium differ from that of a new branded drug launch?
The market for atorvastatin calcium is fundamentally different from a new branded drug launch. New branded drugs typically enter the market with high prices, protected by patents and market exclusivity, with initial pricing driven by R&D costs and perceived therapeutic value. In contrast, atorvastatin calcium is a mature generic with no patent protection, where pricing is driven by manufacturing efficiency, economies of scale, and intense price competition among multiple generic producers.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book [2] Centers for Medicare & Medicaid Services. (n.d.). National Health Expenditure Data. Retrieved from https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthincomedata [3] Various pharmaceutical market data providers (Proprietary data sources for pricing and market share analysis not publicly disclosed).
More… ↓
